Q-omics provides the consensus-scored KIAA0895L profile across patient tissues and cancer cell-line models. KIAA0895L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KIAA0895L is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KIAA0895L RNA expression shows 18,889 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KIRC, and UVM as cancer lineages where KIAA0895L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA0895L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA0895L survival associations across molecular data types. KIAA0895L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA0895L RNA expression–survival associations across cancer types. High KIAA0895L expression shows unfavorable associations in COAD, DLBC, PRAD and BRCA, but favorable associations in PAAD and HNSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for KIAA0895L RNA expression.
This table summarizes KIAA0895L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIAA0895L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA0895L shows higher tumor expression in KIRC, COAD, HNSC, LIHC, BLCA and STAD. The KIRC box plot shows higher KIAA0895L RNA expression in tumor versus normal tissue (log2 FC = +1.073, t-test p < 0.001).
This table shows molecular features associated with KIAA0895L in patient tissues and cancer cell lines. In patient samples, KIAA0895L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA0895L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
